January 20, 2020
CureLab Oncology CEO Alex Shneider’s lament is a biopharma industry that exhibits little appetite for those discoveries made while coloring outside the lines
News
April 29, 2020
CureLab Oncology’s Dr. Alex Shneider Publishes Paper: Can Melatonin Reduce the Severity of COVID-19?
Melatonin may prevent the development of severe disease symptoms in coronavirus patients, reduce the severity of their symptoms, and/or reduce the immuno-pathology of coronavirus infection on patients’ health after the active phase of the infection is over
August 11, 2021
Preliminary clinical results in deadly forms of breast and ovarian cancers have encouraged oncologists to expand the study to include hormone-resistant breast and metastatic prostate cancers; at the center of the study is CureLab Oncology’s Elenagen, an experimental DNA therapy
September 16, 2021
The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy
January 20, 2020
CureLab Oncology CEO Alex Shneider’s lament is a biopharma industry that exhibits little appetite for those discoveries made while coloring outside the lines
April 29, 2020
CureLab Oncology’s Dr. Alex Shneider Publishes Paper: Can Melatonin Reduce the Severity of COVID-19?
Melatonin may prevent the development of severe disease symptoms in coronavirus patients, reduce the severity of their symptoms, and/or reduce the immuno-pathology of coronavirus infection on patients’ health after the active phase of the infection is over
August 11, 2021
Preliminary clinical results in deadly forms of breast and ovarian cancers have encouraged oncologists to expand the study to include hormone-resistant breast and metastatic prostate cancers; at the center of the study is CureLab Oncology’s Elenagen, an experimental DNA therapy
September 16, 2021
The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy